Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.65 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | KDM5A | P29375 | 1/20 | 0.62 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.62 |
| ▸ | NMUR2 | Q9GZQ4 | 6/20 | 0.61 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.61 |
| ▸ | NPY2R | P49146 | 5/20 | 0.59 |
| ▸ | NPY4R | P50391 | 5/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.59 |
| ▸ | NPY1R | P25929 | 4/20 | 0.59 |
| ▸ | TFPI | P10646 | 3/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3357771 | 0.93 | NMUR2 (0.68) | KDM1ANMUR2NMUR1NPY2RNPY4R | |
| SCHEMBL31307220 | 0.93 | NMUR2 (0.60) | KDM1ANMUR2NMUR1KEAP1 | |
| SCHEMBL30495741 | 0.92 | KDM1A (0.70) | KDM1AMAOBKDM5AKDM1BNMUR2 | |
| SCHEMBL30429908 | 0.91 | KDM1A (0.65) | KDM1AMAOBKDM5AKDM1BNPY2R | |
| SCHEMBL30176214 | 0.90 | KDM1A (0.60) | KDM1AMAOBKDM5AKDM1BNMUR2 | |
| SCHEMBL30576992 | 0.89 | KDM1A (0.64) | KDM1AMAOBKDM5AKDM1BNPY2R | |
| SCHEMBL30262061 | 0.89 | KEAP1 (0.61) | KDM1AMAOBKDM5AKDM1BNPY2R | |
| SCHEMBL30168766 | 0.89 | NMUR2 (0.68) | KDM1ANMUR2NMUR1TFPI | |
| SCHEMBL34463649 | 0.89 | NMUR2 (0.68) | KDM1ANMUR2NMUR1NPY2RNPY4R | |
| SCHEMBL29625796 | 0.89 | KDM1A (0.66) | KDM1AMAOBKDM5AKDM1BNMUR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238459-A1 | Granzyme-Activatable Membrane-Interacting Peptides and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-07-18 | — | — | US | claimed |
| US-20240148912-A1 | Activatable Membrane-Interacting Peptides and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-09 | — | — | US | claimed |
| EP-4362966-A1 | GRANZYME-ACTIVATABLE MEMBRANE-INTERACTING PEPTIDES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-08 | — | — | EP | claimed |
| CN-117895469-A | MMC virtual impedance self-adaption method for multi-high-frequency resonance suppression | 中国石油大学(华东) | 2024-04-16 | — | — | CN | claimed |
| CN-117881413-A | Granzyme activatable membrane interaction peptides and methods of use | 加利福尼亚大学董事会 | 2024-04-12 | — | — | CN | claimed |
| CN-115859385-A | Anti-structural attack logic locking encryption device and method for integrated circuit chip | 浙江大学 | 2023-03-28 | — | — | CN | claimed |
| WO-2023278737-A1 | GRANZYME-ACTIVATABLE MEMBRANE-INTERACTING PEPTIDES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-05 | — | — | WO | claimed |
| US-11332515-B2 | Multi-epitopic construct | THROMBOSIS RESEARCH INSTITUTE (GB) | 2022-05-17 | — | — | US | claimed |
| US-20260100700-A1 | DUTY CYCLE CORRECTION CIRCUIT AND METHOD FOR OPERATING THE SAME | TAIWAN SEMICONDUCTOR MFG CO LTD (TW) | 2026-04-09 | — | — | US | disclosed |
| US-12546779-B2 | Binding molecule having neutralizing activity against SARS-coronavirus-2 | CELLTRION, INC. (KR) | 2026-02-10 | — | — | US | disclosed |
| CN-121389201-A | SAT elastic logic locking module for improving output damage, module variant and application | 湖南女子学院 | 2026-01-23 | — | — | CN | disclosed |
| US-12511354-B2 | System, method, and computer-accessible medium for register-transfer level locking against an untrusted foundry | NEW YORK UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250325665-A1 | FUSION CONSTRUCTS AND METHODS OF USING THEREOF | PRECIGEN, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-12387024-B2 | System, method, computer-accessible medium, and circuit for crippling the oracle in logic locking | NEW YORK UNIVERSITY IN ABU DHABI CORPORATION (AE) | 2025-08-12 | — | — | US | disclosed |
| US-11332515-B2 | Multi-epitopic construct | THROMBOSIS RESEARCH INSTITUTE (GB) | 2022-05-17 | — | — | US | disclosed |
| US-20220147598-A1 | SYSTEM, METHOD, AND COMPUTER-ACCESSIBLE MEDIUM FOR REGISTER-TRANSFER LEVEL LOCKING AGAINST AN UNTRUSTED FOUNDRY | POLITECNICO DI MILANO (IT) | 2022-05-12 | — | — | US | disclosed |
| US-20220135984-A1 | MICROBIOME MODULATION OF A HOST BY DELIVERY OF DNA PAYLOADS WITH MINIMIZED SPREAD | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2022-05-05 | — | — | US | disclosed |
| WO-2022090679-A1 | CORONAVIRUS POLYPEPTIDE | Oxford Vacmedix UK Limited (GB) | 2022-05-05 | — | — | WO | disclosed |
| EP-3962514-A1 | METHODS AND COMPOSITIONS INVOLVING TERT ACTIVATING THERAPIES | Board of Regents, The University of Texas System (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3943127-A1 | HEMOSTATIC MATERIAL | Baxter International Inc (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238459-A1 | Granzyme-Activatable Membrane-Interacting Peptides and Methods of Use | GZMB, PRF1, PLA2G2A | KDM1A 4015/4885MAOB 2459/4885KDM5A 4465/4885 |
| US-20240148912-A1 | Activatable Membrane-Interacting Peptides and Methods of Use | ANXA5, F13B, PLA2G2A | KDM1A 4438/4885MAOB 3245/4885KDM5A 3954/4885 |
| US-12546779-B2 | Binding molecule having neutralizing activity against SARS-coronavirus-2 | IGLV6-57, IGSF11, FCGR3B | KDM1A 1970/4885MAOB 4692/4885KDM5A 2086/4885 |
| US-20250325665-A1 | FUSION CONSTRUCTS AND METHODS OF USING THEREOF | MUC1, CD40, TNFRSF1A | KDM1A 2512/4885MAOB 4149/4885KDM5A 2982/4885 |
| US-12511354-B2 | System, method, and computer-accessible medium for register-transfer level locking against an untrusted foundry | APOL1, LPL, LDLR | KDM1A 4772/4885MAOB 3359/4885KDM5A 4807/4885 |
| US-20260100700-A1 | DUTY CYCLE CORRECTION CIRCUIT AND METHOD FOR OPERATING THE SAME | PER2, CRY1, CRY2 | KDM1A 524/4885MAOB 4597/4885KDM5A 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.